Liquidia Stock (NASDAQ:LQDA)
Previous Close
$19.60
52W Range
$8.26 - $19.94
50D Avg
$15.18
200D Avg
$13.62
Market Cap
$1.69B
Avg Vol (3M)
$2.42M
Beta
-0.01
Div Yield
-
LQDA Company Profile
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Performance
Peer Comparison
Ticker | Company |
---|---|
KZR | Kezar Life Sciences, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
KNSA | Kiniksa Pharmaceuticals, Ltd. |
DAWN | Day One Biopharmaceuticals, Inc. |
VRCA | Verrica Pharmaceuticals Inc. |
LRMR | Larimar Therapeutics, Inc. |
SRRK | Scholar Rock Holding Corporation |
MNKD | MannKind Corporation |
UTHR | United Therapeutics Corporation |